Literature DB >> 28973343

Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.

William L Hwang1,2, Andrzej Niemierko2, Katie L Hwang2,3, Harper Hubbeling3,4, Emily Schapira2,3, Justin F Gainor4, Florence K Keane2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 28973343      PMCID： PMC5838581          DOI： 10.1001/jamaoncol.2017.3808

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

1.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

2.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

Authors:  Jeffrey S Weber; F Stephen Hodi; Jedd D Wolchok; Suzanne L Topalian; Dirk Schadendorf; James Larkin; Mario Sznol; Georgina V Long; Hewei Li; Ian M Waxman; Joel Jiang; Caroline Robert
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

3.  Immunologic correlates of the abscopal effect in a patient with melanoma.

Authors:  Michael A Postow; Margaret K Callahan; Christopher A Barker; Yoshiya Yamada; Jianda Yuan; Shigehisa Kitano; Zhenyu Mu; Teresa Rasalan; Matthew Adamow; Erika Ritter; Christine Sedrak; Achim A Jungbluth; Ramon Chua; Arvin S Yang; Ruth-Ann Roman; Samuel Rosner; Brenna Benson; James P Allison; Alexander M Lesokhin; Sacha Gnjatic; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

4.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

5.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245
  6 in total
  31 in total

1.  Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.

Authors:  Sibo Tian; Jeffrey M Switchenko; Zachary S Buchwald; Pretesh R Patel; Joseph W Shelton; Shannon E Kahn; Rathi N Pillai; Conor E Steuer; Taofeek K Owonikoko; Madhusmita Behera; Walter J Curran; Kristin A Higgins
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-01-24       Impact factor: 7.038

2.  Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math.

Authors:  Frank A Giordano; Marlon R Veldwijk; Carsten Herskind; Frederik Wenz
Journal:  Strahlenther Onkol       Date:  2018-07-20       Impact factor: 3.621

3.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

4.  Differential inflammatory response dynamics in normal lung following stereotactic body radiation therapy with protons versus photons.

Authors:  Yanjing Li; Michael Dykstra; Till D Best; Jennifer Pursley; Nitish Chopra; Florence K Keane; Melin J Khandekar; Gregory C Sharp; Harald Paganetti; Henning Willers; Florian J Fintelmann; Clemens Grassberger
Journal:  Radiother Oncol       Date:  2019-04-20       Impact factor: 6.280

Review 5.  Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies.

Authors:  Elizabeth Guimond; Chiaojung Jillian Tsai; Ali Hosni; Grainne O'Kane; Jonathan Yang; Aisling Barry
Journal:  Adv Radiat Oncol       Date:  2022-07-14

6.  Pneumonitis after Stereotactic Thoracic Radioimmunotherapy with Checkpoint Inhibitors: Exploration of the Dose-Volume-Effect Correlation.

Authors:  Kim Melanie Kraus; Caroline Bauer; Benedikt Feuerecker; Julius Clemens Fischer; Kai Joachim Borm; Denise Bernhardt; Stephanie Elisabeth Combs
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

Review 7.  Radiotherapy and Immunotherapy Combinations for Lung Cancer.

Authors:  Vishesh Agrawal; Kimberly Thomas Benjamin; Eric C Ko
Journal:  Curr Oncol Rep       Date:  2020-11-19       Impact factor: 5.075

8.  Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.

Authors:  Khinh Ranh Voong; Sarah Z Hazell; Wei Fu; Chen Hu; Cheng Ting Lin; Kai Ding; Karthik Suresh; Jonathan Hayman; Russell K Hales; Salem Alfaifi; Kristen A Marrone; Benjamin Levy; Christine L Hann; David S Ettinger; Josephine L Feliciano; Valerie Peterson; Ronan J Kelly; Julie R Brahmer; Patrick M Forde; Jarushka Naidoo
Journal:  Clin Lung Cancer       Date:  2019-03-28       Impact factor: 4.785

Review 9.  SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.

Authors:  Yu Chen; Min Gao; Zhaoqin Huang; Jinming Yu; Xiangjiao Meng
Journal:  J Hematol Oncol       Date:  2020-07-28       Impact factor: 17.388

Review 10.  Roadmap: proton therapy physics and biology.

Authors:  Harald Paganetti; Chris Beltran; Stefan Both; Lei Dong; Jacob Flanz; Keith Furutani; Clemens Grassberger; David R Grosshans; Antje-Christin Knopf; Johannes A Langendijk; Hakan Nystrom; Katia Parodi; Bas W Raaymakers; Christian Richter; Gabriel O Sawakuchi; Marco Schippers; Simona F Shaitelman; B K Kevin Teo; Jan Unkelbach; Patrick Wohlfahrt; Tony Lomax
Journal:  Phys Med Biol       Date:  2021-02-26       Impact factor: 4.174
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.